Catheter Precision (VTAK) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 09, 2022
Document Information [Line Items]
Entity Registrant Name	Ra Medical Systems, Inc.
Entity Central Index Key	0001716621
Document Type	10-Q
Document Period End Date	Sep. 30, 2022
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	RMED
Security Exchange Name	NYSEAMER
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		2,161,406
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Ex Transition Period	false
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-38677
Entity Tax Identification Number	38-3661826
Entity Address, Address Line One	5857 Owens Drive, Suite 300
Entity Address, City or Town	Carlsbad
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92009
City Area Code	760
Local Phone Number	804-1648
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes
Former Address [Member]
Document Information [Line Items]
Entity Address, Address Line One	2070 Las Palmas Drive
Entity Address, City or Town	Carlsbad
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92011

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current Assets
Cash and cash equivalents	$ 13,657	$ 15,045
Accounts receivable, net		21
Inventories		986
Prepaid expenses and other current assets	1,885	1,037
Total current assets	15,542	17,089
Property and equipment, net		1,809
Operating lease right-of-use assets	1,893	2,110
Other long-term assets	36	36
TOTAL ASSETS	17,471	21,044
Current Liabilities
Accounts payable	460	988
Accrued expenses	2,447	4,119
Current portion of operating lease liability	308	283
Total current liabilities	3,215	5,390
Operating lease liability	1,746	1,981
Total liabilities	4,961	7,371
Commitments and contingencies (Note 12)
Stockholders’ Equity
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares issued
Common stock, $0.0001 par value; 300,000 shares authorized; 1,423 and 140 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively
Additional paid-in capital	209,488	191,945
Accumulated deficit	(196,978)	(178,272)
Total stockholders’ equity	12,510	13,673
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 17,471	$ 21,044

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	1,423,000	140,000
Common stock, shares outstanding	1,423,000	140,000

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues
Total net revenues		$ 5	$ 14	$ 17
Cost of revenues
Total cost of revenues		246	161	1,213
Gross loss		(241)	(147)	(1,196)
Operating expenses
Selling, general and administrative	$ 3,514	4,211	8,292	11,285
Research and development	727	2,942	6,238	8,521
Restructuring and impairment (Note 13)	542		4,069
Total operating expenses	4,783	7,153	18,599	19,806
Operating loss	(4,783)	(7,394)	(18,746)	(21,002)
Other income, net	20	16	40	2,028
Loss from continuing operations before income taxes	(4,763)	(7,378)	(18,706)	(18,974)
Loss from continuing operations	(4,763)	(7,378)	(18,706)	(18,974)
Discontinued operations
Income from discontinued operations before income taxes		3,080		2,191
Income from discontinued operations		3,080		2,191
Net loss	$ (4,763)	$ (4,298)	$ (18,706)	$ (16,783)
Net (loss) income per share, basic and diluted
Continuing operations, basic	$ (4.36)	$ (57.64)	$ (28)	$ (210.82)
Continuing operations, diluted	(4.36)	(57.64)	(28)	(210.82)
Discontinued operations, basic		24.06		24.34
Discontinued operations, diluted		24.06		24.34
Total net loss per share, basic	(4.36)	(33.58)	(28)	(186.48)
Total net loss per share, diluted	$ (4.36)	$ (33.58)	$ (28)	$ (186.48)
Weighted average number of shares used in computing net (loss) income per share, basic	1,092	128	668	90
Weighted average number of shares used in computing net (loss) income per share, diluted	1,092	128	668	90
Product Sales [Member]
Cost of revenues
Total cost of revenues		$ 68	$ 42	$ 676
Service and Other [Member]
Cost of revenues
Total cost of revenues		$ 178	$ 119	$ 537

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		$ (18,706)	$ (16,783)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash restructuring and impairment		2,943
Depreciation and amortization		396	1,250
Stock-based compensation		365	1,967
Loss (gain) on sales and disposals of property and equipment		44	(489)
Gain on sale of discontinued operations	$ (3,473)		(3,473)
Gain on extinguishment of promissory note			(2,023)
Changes in operating assets and liabilities:
Accounts receivable		21	93
Inventories		(14)	(262)
Prepaid expenses and other assets		(826)	9
Accounts payable		(528)	171
Accrued expenses		(3,028)	(1,875)
Other liabilities		(210)	(265)
Deferred revenue			(234)
Net cash used in operating activities		(19,543)	(21,914)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of discontinued operations			3,700
Payment of fees related to sale of discontinued operations			(227)
Proceeds from sales of property and equipment			554
Purchases of property and equipment			(224)
Net cash provided by investing activities			3,803
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from issuance of common stock and warrants		13,614	15,430
Payments of offering costs related to the issuance of common stock and warrants		(1,168)	(370)
Net proceeds from exercise of warrants		5,704
Proceeds from issuance of common stock in connection with the employee stock purchase plan		5	26
Payments on equipment financing			(265)
Net cash provided by financing activities		18,155	14,821
NET CHANGE IN CASH AND CASH EQUIVALENTS		(1,388)	(3,290)
CASH AND CASH EQUIVALENTS, beginning of period		15,045	23,906	$ 23,906
CASH AND CASH EQUIVALENTS, end of period	$ 20,616	13,657	20,616	$ 15,045
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Unpaid offering costs		1,356
Net proceeds receivable from sales of common stock		379
Proceeds receivable from sales of property and equipment		$ 38
Amounts accrued for purchases of property and equipment			26
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash payments for income taxes			2
Cash payments for interest			$ 2

Condensed Statements of Stockho

Condensed Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Balances at Dec. 31, 2020	$ 21,147		$ 174,349	$ (153,202)
Balance (in shares) at Dec. 31, 2020		63
Common stock issued, net	65		65
Common stock issued, net (in shares)		1
Stock-based compensation	1,169		1,169
Stock-based compensation (In shares)		1
Net loss	(7,236)			(7,236)
Balances at Mar. 31, 2021	15,145		175,583	(160,438)
Balance (in shares) at Mar. 31, 2021		65
Balances at Dec. 31, 2020	21,147		174,349	(153,202)
Balance (in shares) at Dec. 31, 2020		63
Net loss	(16,783)
Balances at Sep. 30, 2021	21,549		191,534	(169,985)
Balance (in shares) at Sep. 30, 2021		140
Balances at Mar. 31, 2021	15,145		175,583	(160,438)
Balance (in shares) at Mar. 31, 2021		65
Common stock issued, net	10,645		10,645
Common stock issued, net (in shares)		52
Common stock issued pursuant to the vesting of restricted stock units and purchases under the employee stock purchase plan	26		26
Stock-based compensation	696		696
Stock-based compensation (In shares)		1
Net loss	(5,249)			(5,249)
Balances at Jun. 30, 2021	21,263		186,950	(165,687)
Balance (in shares) at Jun. 30, 2021		118
Common stock issued, net	4,350		4,350
Common stock issued, net (in shares)		22
Warrant issued	132		132
Stock-based compensation	102		102
Net loss	(4,298)			(4,298)
Balances at Sep. 30, 2021	21,549		191,534	(169,985)
Balance (in shares) at Sep. 30, 2021		140
Balances at Dec. 31, 2021	13,673		191,945	(178,272)
Balance (in shares) at Dec. 31, 2021		140
Common stock and warrants issued, net	9,740		9,740
Common stock and warrants issued, net (in shares)		505
Warrants exercised	25		25
Warrants exercised (in shares)		1
Stock-based compensation	165		165
Net loss	(5,495)			(5,495)
Balances at Mar. 31, 2022	18,108		201,875	(183,767)
Balance (in shares) at Mar. 31, 2022		646
Balances at Dec. 31, 2021	13,673		191,945	(178,272)
Balance (in shares) at Dec. 31, 2021		140
Net loss	(18,706)
Balances at Sep. 30, 2022	12,510		209,488	(196,978)
Balance (in shares) at Sep. 30, 2022		1,423
Balances at Mar. 31, 2022	18,108		201,875	(183,767)
Balance (in shares) at Mar. 31, 2022		646
Common stock issued pursuant to the vesting of restricted stock units and purchases under the employee stock purchase plan	5		5
Restricted stock awards cancelled		(1)
Stock-based compensation	126		126
Net loss	(8,448)			(8,448)
Balances at Jun. 30, 2022	9,791		202,006	(192,215)
Balance (in shares) at Jun. 30, 2022		645
Common stock and warrants issued, net	1,172		1,172
Common stock and warrants issued, net (in shares)		333
Warrants exercised	6,236		6,236
Warrants exercised (in shares)		445
Stock-based compensation	74		74
Net loss	(4,763)			(4,763)
Balances at Sep. 30, 2022	$ 12,510		$ 209,488	$ (196,978)
Balance (in shares) at Sep. 30, 2022		1,423

Organization

Organization	9 Months Ended
	Sep. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization	Note 1. Organization The Company Ra Medical Systems, Inc. (the “Company”) is a medical device company that owns intellectual property related to an advanced excimer laser-based platform for use in the treatment of vascular immune-mediated inflammatory diseases. Its excimer laser and single-use catheter system, together referred to as the DABRA Excimer Laser System, (“DABRA”), is used as a tool in the treatment of peripheral artery disease. The Company was formed on September 4, 2002 in the state of California and reincorporated in Delaware on July 14, 2018. Pending Merger On September 12, 2022, the Company announced entering into an Agreement and Plan of Merger (the “Merger Agreement”) with a privately-held Delaware corporation, Catheter Precision, Inc. (“Catheter”), a medical device and technology company focused in the field of cardiac electrophysiology. Under the terms of the Merger Agreement, Catheter will become a wholly owned subsidiary of the Company in a stock-for-stock reverse merger transaction (the “Merger”). If completed, the Merger will result in a combined publicly traded company that will focus on the cardiac electrophysiology market. The Company’s board of directors and the board of directors of Catheter have approved the Merger, which is currently expected to close before the end of 2022 or early 2023, subject to satisfying certain closing conditions, including the receipt of shareholder approval by both companies. The Company expects that it will need to raise additional financing in an amount of between $2.0 million and $3.0 million in order to consummate the pending merger with Catheter, in order to meet the $8.0 million “Net Cash” closing requirement under the Merger Agreement and additional original listing requirements of the NYSE American. In addition, the Company needs to meet certain minimum pricing conditions under the Merger Agreement and the listing standards of the NYSE American stock exchange in order for the Merger to close and its shares to continue to be listed on the NYSE American. Reverse Stock Split On September 20, 2022, the Company’s board of directors approved a reverse stock split ratio of 1-for-50 (the “Reverse Stock Split”). On the effective date of October 3, 2022, the number of the Company’s issued and outstanding shares of common stock was decreased from 68.2 million shares to 1.4 million shares. The number of authorized shares and par value per common share remained unchanged. No fractional shares were issued as a result of the Reverse Stock Split. Stockholders who would otherwise have been entitled to receive a fractional share received a cash payment in lieu thereof. The financial statements have been retrospectively adjusted to reflect the Reverse Stock Split of the Company’s common stock for all periods presented. NYSE American On August 31, 2022, the Company received a deficiency letter (the “Letter”) from NYSE American indicating that it was not in compliance with NYSE American continued listing standards as set forth in Section 1003(f)(v) of the NYSE American Company Guide because its shares of common stock had been selling for a substantial period of time at a low price per share, which NYSE American determined to be a 30 trading day average price of less than $0.20 per share. The Letter had no immediate effect on the listing or trading of the Company’s common stock, and the common stock continues to trade on NYSE American under the symbol “RMED.” The Company believes that the aforementioned Reverse Stock Split and accompanying increase in the daily share price of its common stock cured the deficiency, however, the Company had not received confirmation from NYSE American as of the date of this Quarterly Report. Reduction in Force and Operations As previously reported, the Company’s board of directors approved a reduction in force (“RIF”) under which approximately 65% of its full-time employees were immediately terminated, effective June 6, 2022, and provided one-time severance payments totaling $0.6 million. In August and September 2022, an additional 20% of the Company’s employees were terminated and were provided one-time severance payments totaling $0.3 million. The purpose of the RIF was to preserve capital with the goal of maximizing the opportunities available to the Company while the board of directors’ reviewed strategic alternatives. See further discussion in Note 13. Restructuring and Impairment Charges As a result of the RIF, the discontinuation of enrollment in the clinical study and the board of directors’ review of strategic alternatives, the Company has paused all engineering and manufacturing activities, including the development of a version of the DABRA catheter that is compatible with a standard interventional guidewire . The Company has also paused research to prove the feasibility of using a DABRA-derived catheter technology to fracture calcium in arteries in a procedure known as lithotripsy. On July 5, 2022, the Company announced the receipt of FDA 510(k) clearance for the DABRA 2.0 catheter as part of the DABRA Excimer Laser System. This catheter includes a braided over jacket to make the catheter more robust and more kink-resistant when navigating tortuous anatomy. This catheter also has a six-month shelf life as a result of multiple design and manufacturing remediations implemented to address prior limitations. The Company has suspended sales of DABRA and currently ha s no plans to commercialize the DABRA 2.0 , pending the closing of the Merger . Going Concern The Company has incurred recurring net losses from operations and negative cash flows from operating activities since inception. As of September 30, 2022, the Company had an accumulated deficit of $197.0 million. For the nine months ended September 30, 2022, the Company used cash of $19.5 million in operating activities. As of September 30, 2022, the Company had cash and cash equivalents of $13.7 million. Management continues to monitor operating costs and seeks to reduce the Company’s current liabilities. Such actions may impair the Company’s ability to proceed with certain strategic activities, and the Company may be unsuccessful at negotiating existing liabilities to the Company’s benefit. If these efforts are unsuccessful, or the Merger is not completed, the Company’s cash position could be negatively impacted and the Company may, among other things, be required to seek other sources of financing, consummate another strategic transaction or be required to liquidate assets and dissolve the Company Management believes that, based on the Company’s liquidity resources and the significant uncertainty regarding its future plans, there is substantial doubt about the Company’s ability to continue as a going concern for a period of at least 12 months from the date of issuance of the financial statements. The Company’s independent registered public accounting firm expressed substantial doubt regarding the Company’s ability to continue as a going concern in its report on the Company’s financial statements as of and for the year ended December 31, 2021. Although the Company improved its liquidity resources during the nine months ended September 30, 2022 through a private placement, proceeds from warrant exercises and sales of common stock under the At-The-Market Sales Agreement with Ladenburg Thalmann & Co., Inc. (the “ATM Agreement”) resulting in total net cash proceeds of $18.2 million, and may receive additional funds from the sale of common stock under the ATM Agreement and exercise of warrants depending on market conditions, management has concluded that the aforementioned conditions continue to raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least 12 months from the date of issuance of the financial statements. Management plans to address this uncertainty by raising additional funds, if necessary, through public or private equity or debt financings as well as by engaging in regular and ongoing reviews of its strategic options to help ensure that the Company is focusing its cash resources on advancing its key corporate initiatives. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty. COVID-19 The global effects of COVID-19 have created significant volatility, uncertainty and economic disruption. Although restrictions have been recently eased around the world, the COVID-19 pandemic is still ongoing, and the ultimate effects of COVID-19 on the Company’s business, operations and financial condition are unknown at this time. The Company expects that patient follow-up in its atherectomy clinical trial may continue to be affected by the uncertainty relating to COVID-19, as patients may continue to elect to postpone follow-up visits and physicians’ offices may intermittently close or operate at a reduced capacity in response to COVID-19. The extent to which COVID-19 impacts the Company’s business will depend on future developments which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain it or treat its impact, among others.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Significant Accounting Policies Basis of Presentation The unaudited interim condensed financial statements have been prepared on the same basis as the annual financial statements and reflect all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s condensed balance sheets, results of operations, cash flows and statements of stockholders’ equity for the periods presented. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other future annual or interim period. The balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date. These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 24, 2022, and as amended on July 13, 2022. Use of Estimates The preparation of interim unaudited condensed financial statements in accordance with generally accepted accounting principles in the United States (“GAAP”) Fair Value Measurements Fair value represents the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants and is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier value hierarchy is used to identify inputs used in measuring fair value as follows: Level 1 – Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; Level 2 – Inputs other than the quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and Level 3 – Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. The hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. Fair Value of Financial Instruments Cash and cash equivalents, trade accounts receivable, accounts payable, accrued expenses and other current assets and liabilities are reported on the balance sheets at carrying value which approximates fair value due to the short-term maturities of these instruments. Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Cost includes materials, labor and manufacturing overhead related to the purchase and production of inventories. The Company reduces the carrying value of inventories for those items that are potentially excess or obsolete based on changes in customer demand, technological developments or other economic factors. Prior to June 6, 2022, the Company’s catheters were manufactured in-house, and each catheter was tested at various stages of the manufacturing process for adherence to quality standards. Catheters that did not meet functionality specification at each test point were destroyed and immediately written off. Once manufactured, completed catheters that passed quality assurance were sent to a third-party for sterilization and sealed in a sterile container. Upon return from the third-party sterilizer, a sample of catheters from each batch was re-tested. If the sample tests were successful, the batch was accepted into finished goods inventory. If the sample tests were unsuccessful, the entire batch was written off. Impairment of Long-Lived Assets The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the long-lived assets, including its eventual residual values, is compared to the carrying value to determine whether impairment exists. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Segment Information The Company operates its business in one segment which includes all activities related to the research, development and manufacture of the DABRA system. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment. Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting , Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) .

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2022
Payables And Accruals [Abstract]
Discontinued Operations	Note 3. Discontinued Operations The Company completed the sale of its Pharos dermatology business (the “Dermatology Business”) to STRATA Skin Sciences, Inc. (“Strata”) on August 16, 2021 for net proceeds of $3.7 million, resulting in a gain on the sale of the Dermatology Business of $3.5 million which was included as a component of income (loss) from discontinued operations in the statement of operations for the year ended December 31, 2021. The Dermatology Business was previously disclosed as a separate reportable segment of the Company. The results of the Dermatology Business are reported as loss from discontinued operations in the condensed statements of operations for the three and nine months ended September 30, 2021. Certain overhead costs previously allocated to the Dermatology Business for segment reporting purposes did not qualify for classification as discontinued operations and have been reallocated to continuing operations for the three and nine months ended September 30, 2021. The following table summarizes the loss from discontinued operations in the condensed statements of operations for the periods presented (in thousands): Three Months Ended September 30, 2021 Nine Months Ended September 30, 2021 Revenues $ 489 $ 2,600 Cost of revenues 396 2,290 Gross income 93 310 Operating expenses 464 1,498 Operating loss (371 ) (1,188 ) Other expense, net (22 ) (94 ) Gain on sale of Dermatology Business 3,473 3,473 Income from discontinued operations $ 3,080 $ 2,191 Depreciation expense for the Dermatology Business was $0.1 million and $0.3 million for the three and nine months ended September 30, 2021, respectively. There were no capital expenditures for the Dermatology Business during the three and nine months ended September 30, 2021. Stock-based compensation expense for the Dermatology Business was de minimis

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 4. Fair Value Measurements As of September 30, 2022 and December 31, 2021, cash equivalents of approximately $1.4 million and $15.0 million, respectively, were categorized as Level 1 and consisted of money market funds that were measured at fair value on a recurring basis.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventories	Inventories consisted of the following (in thousands): September 30, 2022 December 31, 2021 Raw materials $ — $ 911 Work in process — 70 Finished goods — 5 Total inventories $ — $ 986 Due to the RIF and the Company’s decision to discontinue enrollment of patients in its clinical trial, the Company suspended manufacturing activities in June 2022 and disposed of substantially all inventories in July 2022, resulting in a write-down of $1.0 million in its inventories to net realizable value. Such expense is included in restructuring and impairment charges in the condensed statements of operations for the nine months ended September 30, 2022. See Note 13. Restructuring and Impairment Charges.

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2022
Property Plant And Equipment Net [Abstract]
Property and Equipment	Note 6. Property and Equipment Property and equipment consisted of the following (in thousands): September 30, 2022 December 31, 2021 Furniture and fixtures $ — $ 48 Machinery and equipment — 858 Lasers — 3,085 Computer hardware and software — 353 Construction in progress — 169 Leasehold improvements — 145 Property and equipment, gross — 4,658 Accumulated depreciation — (2,849 ) Total property and equipment, net $ — $ 1,809 Depreciation expense was nil and $0.2 million for the three months ended September 30, 2022 and 2021, respectively, and $0.2 million and $0.7 million for the nine months ended September 30, 2022 and 2021, respectively. Due to the Company’s decision to discontinue enrollment of patients in its clinical trial and the RIF, the Company suspended manufacturing activities in June 2022. The Company’s property and equipment was determined to be impaired as of June 30, 2022, resulting in an impairment charge of $1.5 million which was based on the actual cash proceeds received upon the disposal of the property and equipment in July 2022. The impairment charge of $1.5 million is included in restructuring and impairment charges in the condensed statements of operations for the nine months ended September 30, 2022. See Note 13. Restructuring and Impairment Charges.

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2022
Payables And Accruals [Abstract]
Accrued Expenses	Note 7. Accrued Expenses Accrued expenses consisted of the following (in thousands): September 30, 2022 December 31, 2021 Offering costs $ 1,356 $ — Legal expenses 590 1,345 Warranty expenses 192 195 Compensation and related benefits 148 2,004 Other accrued expenses 161 575 Total accrued expenses $ 2,447 $ 4,119

Lease

Lease	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Lease	Note 8. Lease The Company has an operating lease for office and manufacturing space which requires it to pay base rent and certain utilities. Monthly rent expense is recognized on a straight-line basis over the term of the lease which expires in 2027. At September 30, 2022, the remaining lease term was 5.25 years. The operating lease is included in the condensed balance sheets at the present value of the lease payments at a 7% discount rate which approximates the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment on the lease commencement date, as the lease does not provide an implicit rate. For each of the three months ended September 30, 2022 and 2021, operating lease expense and cash paid for leases was $ de minimis . See Note 14. Subsequent Events. Maturities of operating lease liabilities consisted of the following as of September 30, 2022 (in thousands): Years Ending December 31, 2022 (remaining three months) $ 108 2023 445 2024 459 2025 472 2026 486 Thereafter 501 Total operating lease payments 2,471 Less: imputed interest (417 ) Total operating lease liability $ 2,054

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Loss per Share	Note 9. Net Loss per Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the reporting period. A net loss cannot be diluted, so when the Company is in a net loss position, basic and diluted loss per common share are the same. If in the future the Company achieves profitability, the denominator of a diluted earnings per common share calculation will include both the weighted average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents include warrants, stock options, non-vested restricted stock units and employee stock purchase plan rights. The Company’s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company. Anti-dilutive share equivalents excluded from the computation of diluted net loss per share at September 30, 2022 consisted of warrants of 1,150,686, stock options of 1,427, restricted stock awards of 1,354 and restricted stock units of 75. Anti-dilutive share equivalents excluded from the computation of diluted net loss per share at September 30, 2021 consisted of warrants of 48,373, stock options of 2,539, restricted stock awards of 6,247, restricted stock units of 916 and Employee Stock Purchase Plan shares of 209.

Equity Offerings

Equity Offerings	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Equity Offerings	Note 10. Equity Offerings At-The-Market Sales Agreement On September 2, 2022, the Company entered into the ATM Agreement under which the Company could sell its common stock from time to time having an aggregate offering price of up to $7.6 million. The Company sold 333,184 shares of common stock under the offering through September 30, 2022, resulting in net proceeds of $2.5 million, after deducting offering fees. Net proceeds receivable of $0.4 million at September 30, 2022 relates to sales of common stock under the ATM Agreement prior to or on September 30, 2022 that settled after that date. See Note 14. Subsequent Events Warrant Repricing On July 22, 2022, the Company reduced the exercise price of all outstanding warrants, consisting of Series A warrants and Series B warrants, that were issued in the public offering on February 8, 2022 (the “Offering”) from $25.00 per share to $14.00 per share (the “Warrant Repricing”). Following the Warrant Repricing, the Company entered into warrant inducement offer letters (the “Inducement Letters”) with certain investors. In response to the Inducement Letters, investors exercised approximately 0.4 million Series A warrants and no Series B warrants. Investors who exercised their Series A warrants received Series C warrants to purchase 100% of the shares exercised pursuant to the Series A warrants, The Series C warrants have an exercise price of $14.00, are immediately exercisable and expire in five years. The Company received net proceeds of approximately $ 4.9 million from the exercises of the Series A warrants , after deducting underwriter commissions and fees withheld of $ 0.6 million and other offering expenses paid or payable of $ million . The Warrant Repricing resulted in an immediate and incremental increase of approximately $2.3 million in the estimated fair value of the Series A warrants and Series B warrants issued in the Company’s February 2022 public offering (the “Offering”). The Series A warrants and Series B warrants were valued on the date of the Warrant Repricing using the Black-Scholes option pricing model (“Black-Scholes model”) based on the following assumptions: Series A Series B Risk-free interest rate 2.97 % 2.85 % Volatility 137.87 % 90.44 % Expected dividend yield 0.00 % 0.00 % Expected life (in years) 0.6 6.6 The Series C warrants were valued at approximately $2.3 million using the Black-Scholes model based on the following assumptions: Risk-free interest rate 2.87 % Volatility 96.70 % Expected dividend yield 0.00 % Expected life (in years) 5.0 The Company is contractually obligated to pay a former placement agent a cash tail fee equal to 7.5% cash compensation for the gross proceeds raised and to issue warrants equal to 7.0% of the number of shares of common stock sold to any investor contacted by the former placement during the term of its engagement with the Company (“Tail Fees”). Thus, the Company is obligated to pay such placement agent Tail Fees related to the Warrant Repricing consisting of cash tail fees of approximately $0.5 million and to issue a warrant to purchase approximately 31,000 shares of common stock with an exercise price of $17.50 per share which represents 125% of the exercise price of the Series C warrants issued pursuant to the Inducement Letters. Such warrant would be immediately exercisable and expire five years from its issuance date. This warrant was valued at approximately $0.2 million on the Warrant Repricing date using the Black-Scholes model based on the following assumptions: expected volatility of 96.7%, risk-free interest rate of 2.87%, expected dividend yield of 0% and an expected term of 5.0 years. This warrant has not been issued by the Company as of the date of this Quarterly Report. The cash tail fees are included in accrued expenses in the condensed balance sheet as of September 30, 2022. Public Offering On February 8, 2022, the Company completed the Offering in which it issued and sold (i) 190,700 shares of common stock, (ii) 480,052 warrants to purchase one share of common stock at an exercise price of $25.00 that were immediately exercisable and expire one year from the date of issuance, or Series A warrants, and (iii) 480,052 warrants to purchase one share of common stock at an exercise price of $25.00 that were immediately exercisable and expire seven years from the date of issuance, or Series B warrants, and (iv) 289,352 pre-funded warrants to purchase one share of common stock at an exercise price of $0.005 per share that were immediately exercisable and expire twenty years from the date of issuance. In addition, the Company granted the underwriters of the Offering a 45-day option (the “Overallotment Option”) to purchase up to (i) 72,000 additional shares of common stock, (ii) 72,000 additional Series A warrants and/or (iii) 72,000 additional Series B warrants, solely to cover overallotments. The Series A warrants and Series B warrants were valued at approximately $11.6 million using the Black-Scholes model based on the following assumptions: Series A Series B Risk-free interest rate 0.91 % 1.93 % Volatility 131.07 % 85.38 % Expected dividend yield 0.00 % 0.00 % Expected life (in years) 1.0 7.0 Pursuant to the exercise of the Overallotment Option in February 2022, the Company issued 24,902 shares of common stock, 72,000 Series A warrants and 72,000 Series B warrants, net of underwriting discounts. On various dates in February 2022 and March 2022, the Company issued 289,352 shares of common stock upon the exercise of all of the pre-funded warrants issued in the Offering. In addition, in March 2022, the Company issued 1,000 shares of common stock in connection with the exercise of each of Series A warrants and Series B warrants issued in the Offering. In July 2022, the Company issued 800 shares of common stock in connection with the exercise of 800 Series A warrants issued in the Offering. Net proceeds from the Offering were approximately $9.7 million, after deducting underwriter commissions and fees withheld of approximately $1.1 million and offering expenses paid or payable of $1.8 million. The Company is contractually obligated to pay a former placement agent Tail Fees related to the Offering consisting of cash tail fees of approximately $0.9 million and a warrant to purchase approximately 33,000 shares of common stock at an exercise price of $31.25 per share, which represents 125% of the exercise price in the Offering. The cash tail fees are included in accrued expenses in the condensed balance sheet as of September 30, 2022. Warrants Outstanding At September 30, 2022, the Company had 1,150,686 shares of common stock reserved for issuance pursuant to the warrants issued by the Company at a weighted average exercise price of $33.67.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	Note 11. Stock-Based Compensation A summary of the activity and related data by award type under the 2018 Equity Incentive Plan and the 2020 Inducement Equity Incentive Plan (collectively, the “Plans”) for the nine months ended September 30, 2022 is set forth below: Stock Options Stock Options Weighted Average Exercise Price Weighted Average Remaining Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2021 2,168 $ 17,277 Canceled/forfeited (741 ) $ 19,266 Outstanding at September 30, 2022 1,427 $ 16,244 4.07 $ — Exercisable at September 30, 2022 1,251 $ 18,342 3.60 $ — Vested and expected to vest at September 30, 2022 1,427 $ 16,244 4.07 $ — Restricted Stock Units Restricted Stock Units Weighted Average Grant Date Fair Value Outstanding at December 31, 2021 1,400 $ 219 Vested (117 ) $ 609 Canceled/forfeited (1,208 ) $ 168 Outstanding at September 30, 2022 75 $ 416 Restricted Stock Awards Restricted Stock Awards Weighted Average Grant Date Fair Value Outstanding at December 31, 2021 3,586 $ 236 Vested (1,266 ) $ 239 Canceled/forfeited (966 ) $ 211 Outstanding at September 30, 2022 1,354 $ 249 The following table summarizes stock-based compensation expense for the Plans included in operating expenses for the periods presented (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Selling, general and administrative $ 85 $ 78 $ 302 $ 1,551 Research and development (11 ) 27 57 251 Stock-based compensation in operating expenses $ 74 $ 105 $ 359 $ 1,802 Stock-based compensation expense of nil and approximately $5,000 was capitalized to inventory and property and equipment during the three months ended September 30, 2022 and 2021, respectively. Stock-based compensation expense of approximately $6,000 and $0.1 million was capitalized to inventory and property and equipment during the nine months ended September 30, 2022 and 2021, respectively. Unrecognized stock-based compensation expense by award type and the remaining weighted average recognition period over which such expense is expected to be recognized as of September 30, 2022 was as follows: Unrecognized Expense (in thousands) Remaining Weighted Average Recognition Period (in years) Stock options $ 122 1.3 Restricted stock awards $ 233 1.4 Restricted stock units $ 20 1.2

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	N ote 12. Commitments and Contingencies Securities Class Action and Shareholder Derivative Litigation Update On June 7, 2019, a putative securities class action complaint captioned Derr v. Ra Medical Systems, Inc., et al, The settlement provides for a payment to the plaintiff class of $10.0 million. The proposed settlement required both preliminary and final approval by the court. On February 11, 2022, the court granted preliminary approval of the settlement, scheduled a hearing on final approval of the settlement and denied the pending motion to dismiss without prejudice. On May 2, 2022, plaintiffs filed a motion for final approval of the settlement and plan of allocation, and lead counsel filed a motion for an award of attorneys’ fees and reimbursement of litigation expenses. On September 23, 2022, the court granted final approval of the settlement, certified the settlement class, granted in part lead counsel’s motion for an award of attorneys’ fees and reimbursement of litigation expenses, dismissed plaintiffs’ claims with prejudice, and entered final judgment. On October 1, 2019, a shareholder derivative complaint captioned Noel Borg v. Dean Irwin, et al Settlement Agreements with the Department of Justice and Participating States As previously announced on December 28, 2020, the Company entered into a Settlement Agreement with the U.S., acting through the Department of Justice and on behalf of the Office of Inspector General, and other settlement agreements with certain state attorneys general to resolve investigations and a related civil action concerning its marketing of the DABRA laser system and DABRA-related remuneration to certain physicians. Pursuant to the terms of the Settlement Agreement and the agreements with the participating states, (a) if the Company’s revenue exceeds $10 million in any of fiscal years 2021-2024, the Company also is required to pay for the corresponding year: $500,000 for 2021, $750,000 for 2022, $1 million for 2023, and $1.25 million for 2024; (b) if the Company is acquired or is otherwise involved in a change in control transaction before the end of 2024, the Company is required to pay an additional settlement amount of $5 million, plus 4% of the value attributed to the Company in the transaction, so long as the attributed value is in excess of $100 million, with the total change in control payment never to exceed $28 million; and (c) if the Company’s obligations under the Settlement Agreement are avoided by bankruptcy, the U.S. may rescind the releases and bring an action against the Company in which the Company agrees is not subject to an automatic stay, is not subject to any statute of limitations, estoppel or laches defense, and is a valid claim in the amount of $56 million, minus any prior change in control payments. Filing of Complaint On September 29, 2022, a purported stockholder of the Company filed a complaint captioned David Nguyen v. Ra Medical Systems, Inc. et al. unable to make a meaningful estimate of the amount of range of loss, if any, that could result from any unfavorable outcome. The Company denies the allegations of the Complain t and intends to defend against the Complaint vigorously. Other Litigation In the normal course of business, the Company is at times subject to pending and threatened legal actions. In management’s opinion, any potential loss resulting from the resolution of these matters will not have a material effect on the results of operations, financial position or cash flows of the Company.

Restructuring and Impairment Ch

Restructuring and Impairment Charges	9 Months Ended
	Sep. 30, 2022
Restructuring And Related Activities [Abstract]
Restructuring and Impairment Charges	Note 13. Restructuring and Impairment Charges Restructuring and impairment charges consisted of the following (in thousands): Three Months Ended Nine Months Ended September 30, 2022 Impairment of property and equipment $ — $ 1,548 Inventory obsolescence — 1,000 Severance expense 326 910 Prepaid expenses — 395 Contract termination fees 216 216 Total restructuring and impairment charges $ 542 $ 4,069 The Company’s RIF impacted approximately 85% of its full-time employees, resulting in one-time severance payments totaling approximately $0.9 million. In addition, the Company decided to discontinue enrollment of patients in its clinical trial, cease engineering and manufacturing activities, sell or dispose of substantially all of its property and equipment, inventories and research and development supplies, resulting in impairment and inventory obsolescence charges and the write-off of prepaid research and development supplies totaling approximately $2.9 million. As of September 30, 2022, the accrued liability balance related to severance expense was approximately $28,000 and is included in accrued expenses in the accompanying condensed balance sheet.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 14. Subsequent Events Completion of Offering On October 7, 2022, pursuant to the ATM Agreement, the Company completed the sale of 1.1 million shares of common stock under the offering, at a weighted average price of $7.09 per share, resulting in net proceeds of approximately $7.4 million, after deducting offering fees of approximately $0.2 million. Termination of Lease Agreement On October 24, 2022, the Company entered into a lease termination agreement with Anaya Holdings LLC (the “Landlord”) (the “Lease Termination Agreement”) pursuant to which it terminated its lease agreement for its corporate headquarters in Carlsbad, California, effective October 28, 2022. In accordance with the terms of the Lease Termination Agreement, the Company has agreed to (i) release its right to the security deposit of approximately $36,000 previously paid to the Landlord and (ii) pay a $0.3 million termination fee to the Landlord. Entry into Lease Agreement On October 31, 2022, the Company entered into a month-to-month lease agreement (the “Lease Agreement”) with Avanti Workspace for its corporate headquarters in Carlsbad, California, effective November 1, 2022. The rent expense under the Lease Agreement is approximately $1,000 per month.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited interim condensed financial statements have been prepared on the same basis as the annual financial statements and reflect all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company’s condensed balance sheets, results of operations, cash flows and statements of stockholders’ equity for the periods presented. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other future annual or interim period. The balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date. These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 24, 2022, and as amended on July 13, 2022.
Use of Estimates	Use of Estimates The preparation of interim unaudited condensed financial statements in accordance with generally accepted accounting principles in the United States (“GAAP”)
Fair Value Measurements	Fair Value Measurements Fair value represents the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants and is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier value hierarchy is used to identify inputs used in measuring fair value as follows: Level 1 – Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; Level 2 – Inputs other than the quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and Level 3 – Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. The hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Cash and cash equivalents, trade accounts receivable, accounts payable, accrued expenses and other current assets and liabilities are reported on the balance sheets at carrying value which approximates fair value due to the short-term maturities of these instruments.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Cost includes materials, labor and manufacturing overhead related to the purchase and production of inventories. The Company reduces the carrying value of inventories for those items that are potentially excess or obsolete based on changes in customer demand, technological developments or other economic factors. Prior to June 6, 2022, the Company’s catheters were manufactured in-house, and each catheter was tested at various stages of the manufacturing process for adherence to quality standards. Catheters that did not meet functionality specification at each test point were destroyed and immediately written off. Once manufactured, completed catheters that passed quality assurance were sent to a third-party for sterilization and sealed in a sterile container. Upon return from the third-party sterilizer, a sample of catheters from each batch was re-tested. If the sample tests were successful, the batch was accepted into finished goods inventory. If the sample tests were unsuccessful, the entire batch was written off.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the long-lived assets, including its eventual residual values, is compared to the carrying value to determine whether impairment exists. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values.
Segment Information	Segment Information The Company operates its business in one segment which includes all activities related to the research, development and manufacture of the DABRA system. The chief operating decision-maker reviews the operating results on an aggregate basis and manages the operations as a single operating segment.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting , Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) .

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Summary of Loss from Discontinued Operations	The following table summarizes the loss from discontinued operations in the condensed statements of operations for the periods presented (in thousands): Three Months Ended September 30, 2021 Nine Months Ended September 30, 2021 Revenues $ 489 $ 2,600 Cost of revenues 396 2,290 Gross income 93 310 Operating expenses 464 1,498 Operating loss (371 ) (1,188 ) Other expense, net (22 ) (94 ) Gain on sale of Dermatology Business 3,473 3,473 Income from discontinued operations $ 3,080 $ 2,191

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consisted of the following (in thousands): September 30, 2022 December 31, 2021 Raw materials $ — $ 911 Work in process — 70 Finished goods — 5 Total inventories $ — $ 986

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2022
Property Plant And Equipment Net [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following (in thousands): September 30, 2022 December 31, 2021 Furniture and fixtures $ — $ 48 Machinery and equipment — 858 Lasers — 3,085 Computer hardware and software — 353 Construction in progress — 169 Leasehold improvements — 145 Property and equipment, gross — 4,658 Accumulated depreciation — (2,849 ) Total property and equipment, net $ — $ 1,809

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2022
Payables And Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following (in thousands): September 30, 2022 December 31, 2021 Offering costs $ 1,356 $ — Legal expenses 590 1,345 Warranty expenses 192 195 Compensation and related benefits 148 2,004 Other accrued expenses 161 575 Total accrued expenses $ 2,447 $ 4,119

Lease (Tables)

Lease (Tables)	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities consisted of the following as of September 30, 2022 (in thousands): Years Ending December 31, 2022 (remaining three months) $ 108 2023 445 2024 459 2025 472 2026 486 Thereafter 501 Total operating lease payments 2,471 Less: imputed interest (417 ) Total operating lease liability $ 2,054

Equity Offerings (Tables)

Equity Offerings (Tables)	9 Months Ended
	Sep. 30, 2022
Series A Warrants and Series B Warrants [Member] | Warrants Repricing [Member]
Schedule of Black-Scholes Option Pricing Model Based on Assumptions	The Series A warrants and Series B warrants were valued on the date of the Warrant Repricing using the Black-Scholes option pricing model (“Black-Scholes model”) based on the following assumptions: Series A Series B Risk-free interest rate 2.97 % 2.85 % Volatility 137.87 % 90.44 % Expected dividend yield 0.00 % 0.00 % Expected life (in years) 0.6 6.6
Series A Warrants and Series B Warrants [Member] | Offering [Member]
Schedule of Black-Scholes Option Pricing Model Based on Assumptions	The Series A warrants and Series B warrants were valued at approximately $11.6 million using the Black-Scholes model based on the following assumptions: Series A Series B Risk-free interest rate 0.91 % 1.93 % Volatility 131.07 % 85.38 % Expected dividend yield 0.00 % 0.00 % Expected life (in years) 1.0 7.0
Series C Warrants [Member] | Warrants Repricing [Member]
Schedule of Black-Scholes Option Pricing Model Based on Assumptions	The Series C warrants were valued at approximately $2.3 million using the Black-Scholes model based on the following assumptions: Risk-free interest rate 2.87 % Volatility 96.70 % Expected dividend yield 0.00 % Expected life (in years) 5.0

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Options Activity	Stock Options Stock Options Weighted Average Exercise Price Weighted Average Remaining Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2021 2,168 $ 17,277 Canceled/forfeited (741 ) $ 19,266 Outstanding at September 30, 2022 1,427 $ 16,244 4.07 $ — Exercisable at September 30, 2022 1,251 $ 18,342 3.60 $ — Vested and expected to vest at September 30, 2022 1,427 $ 16,244 4.07 $ —
Schedule of Restricted Stock Units Activity	Restricted Stock Units Restricted Stock Units Weighted Average Grant Date Fair Value Outstanding at December 31, 2021 1,400 $ 219 Vested (117 ) $ 609 Canceled/forfeited (1,208 ) $ 168 Outstanding at September 30, 2022 75 $ 416
Schedule of Restricted Stock Awards Activity	Restricted Stock Awards Restricted Stock Awards Weighted Average Grant Date Fair Value Outstanding at December 31, 2021 3,586 $ 236 Vested (1,266 ) $ 239 Canceled/forfeited (966 ) $ 211 Outstanding at September 30, 2022 1,354 $ 249
Schedule of Stock-based Compensation Expense Included in Operating Expenses	The following table summarizes stock-based compensation expense for the Plans included in operating expenses for the periods presented (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Selling, general and administrative $ 85 $ 78 $ 302 $ 1,551 Research and development (11 ) 27 57 251 Stock-based compensation in operating expenses $ 74 $ 105 $ 359 $ 1,802
Schedule of Unrecognized Estimated Stock Based Compensation Expense by Award Type	Unrecognized stock-based compensation expense by award type and the remaining weighted average recognition period over which such expense is expected to be recognized as of September 30, 2022 was as follows: Unrecognized Expense (in thousands) Remaining Weighted Average Recognition Period (in years) Stock options $ 122 1.3 Restricted stock awards $ 233 1.4 Restricted stock units $ 20 1.2

Restructuring and Impairment _2

Restructuring and Impairment Charges (Tables)	9 Months Ended
	Sep. 30, 2022
Restructuring And Related Activities [Abstract]
Schedule of Restructuring and Impairment Charges	Restructuring and impairment charges consisted of the following (in thousands): Three Months Ended Nine Months Ended September 30, 2022 Impairment of property and equipment $ — $ 1,548 Inventory obsolescence — 1,000 Severance expense 326 910 Prepaid expenses — 395 Contract termination fees 216 216 Total restructuring and impairment charges $ 542 $ 4,069

Organization - Additional Infor

Organization - Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands			1 Months Ended	2 Months Ended	3 Months Ended	9 Months Ended
	Sep. 20, 2022	Jun. 06, 2022	Jul. 31, 2022	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Oct. 03, 2022	Sep. 12, 2022	Aug. 31, 2022	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Net cash requirement for merger and listing									$ 8,000
Reverse stock split ratio, description	On September 20, 2022, the Company’s board of directors approved a reverse stock split ratio of 1-for-50 (the “Reverse Stock Split”).
Common stock, shares issued	68,200			1,423	1,423	1,423					140
Common stock, shares outstanding	68,200			1,423	1,423	1,423					140
One-time severance payments		$ 600		$ 300	$ 326	$ 910
Accumulated deficit				196,978	196,978	196,978					$ 178,272
Cash and cash equivalents				$ 13,657	$ 13,657	13,657					$ 15,045
Net cash used in operating activities						$ 19,543	$ 21,914
ATM Offering [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Proceeds from warrant exercises and sales of common stock			$ 18,200
Board of Directors [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Percentage of full time employees terminated				20%
Subsequent Event [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Common stock, shares issued								1,400
Common stock, shares outstanding								1,400
Minimum [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Additional expected financing to consummate pending merger									2,000
Maximum [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Additional expected financing to consummate pending merger									$ 3,000
Average price per share										$ 0.20
Maximum [Member] | Board of Directors [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Percentage of full time employees terminated		65%				85%

Significant Accounting Polici_3

Significant Accounting Policies - Additional Information (Details) - Segment	9 Months Ended
	Sep. 30, 2022	Jan. 01, 2022
Accounting Policies [Line Items]
Number of operating segments	1
ASU 2020-06 [Member]
Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adoption Date		Jan. 01, 2022
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]		true
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]		true

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Dec. 31, 2021	Aug. 16, 2021
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Gain on disposition of business	$ 3,473,000	$ 3,473,000
Dermatology [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Depreciation expense	100,000	300,000
Capital expenditure	0	0
Stock based compensation expense	18,000	18,000
Stock based compensation expense capitalized to inventory and property and equipment	$ 4,000	$ 100,000
Dermatology [Member] | Disposition by Sale [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Gain on disposition of business			$ 3,500,000
Dermatology [Member] | Discontinued Operations [Member] | Disposition by Sale [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Cash on disposition of business				$ 3,700,000

Discontinued Operations - Summa

Discontinued Operations - Summary of Loss from Discontinued Operations in Condensed Statements of Operations (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Discontinued Operations And Disposal Groups [Abstract]
Revenues	$ 489	$ 2,600
Cost of revenues	396	2,290
Gross income	93	310
Operating expenses	464	1,498
Operating loss	(371)	(1,188)
Other expense, net	(22)	(94)
Gain on sale of Dermatology Business	3,473	3,473
Income from discontinued operations	$ 3,080	$ 2,191

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Money Market Funds [Member] | Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value disclosure of cash equivalents	$ 1.4	$ 15

Inventories (Details)

Inventories (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Inventory Disclosure [Abstract]
Raw materials	$ 911
Work in process	70
Finished goods	5
Total inventories	$ 986

Inventories - Additional Inform

Inventories - Additional Information (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Inventory [Line Items]
Inventory write-down	$ 1,000
Restructuring and Impairment Charges [Member]
Inventory [Line Items]
Inventory write-down	$ 1,000

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 4,658
Accumulated depreciation	(2,849)
Total property and equipment, net	1,809
Furniture and Fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	48
Machinery and Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	858
Lasers [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	3,085
Computer Hardware and Software [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	353
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	169
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 145

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property Plant And Equipment [Line Items]
Depreciation expense	$ 200	$ 200	$ 700
Impairment of long-lived assets to be disposed of		1,500
Restructuring costs and asset impairment charges		2,943
Property, Plant and Equipment [Member]
Property Plant And Equipment [Line Items]
Restructuring costs and asset impairment charges		$ 1,500

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Payables And Accruals [Abstract]
Offering costs	$ 1,356
Legal expenses	590	$ 1,345
Warranty expenses	192	195
Compensation and related benefits	148	2,004
Other accrued expenses	161	575
Total accrued expenses	$ 2,447	$ 4,119

Lease - Additional Information

Lease - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating Leased Assets [Line Items]
Operating lease, discount rate	7%		7%
Operating lease, remaining lease term	5 years 3 months		5 years 3 months
Operating lease , cash payment	$ 0.1	$ 0.1	$ 0.2	$ 0.4
Operating lease right-of-use-assets amortization	$ 0.1	$ 0.1	$ 0.1	$ 0.3
Office and Manufacturing Space [Member]
Operating Leased Assets [Line Items]
Lease expiration period			2027

Lease - Schedule of Maturities

Lease - Schedule of Maturities of Operating Lease Liabilities (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Leases [Abstract]
2022 (remaining three months)	$ 108
2023	445
2024	459
2025	472
2026	486
Thereafter	501
Total operating lease payments	2,471
Less: imputed interest	(417)
Total operating lease liability	$ 2,054

Net Loss per Share - Additional

Net Loss per Share - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Loss allocated to participating securities	$ 0
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive share equivalents excluded from computation of diluted net loss per share	1,427	2,539
Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive share equivalents excluded from computation of diluted net loss per share	1,150,686	48,373
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive share equivalents excluded from computation of diluted net loss per share	75	916
Restricted Stock Awards (RSAs) [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive share equivalents excluded from computation of diluted net loss per share	1,354	6,247
Employee Stock Purchase Plan [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive share equivalents excluded from computation of diluted net loss per share		209

Equity Offerings - Additional I

Equity Offerings - Additional Information (Details) - USD ($)				1 Months Ended				3 Months Ended	9 Months Ended
	Sep. 02, 2022	Jul. 22, 2022	Feb. 08, 2022	Sep. 30, 2022	Jul. 31, 2022	Mar. 31, 2022	Feb. 28, 2022	Sep. 30, 2022	Sep. 30, 2022
Class Of Stock [Line Items]
Common stock reserve for issuance				1,150,686				1,150,686	1,150,686
Common stock, weighted average exercise price									$ 33.67
Series A Warrants [Member]
Class Of Stock [Line Items]
Proceeds from issuance of common stock		$ 4,900,000
Stock issued during period, warrants exercised		400,000
Percentage of shares exercised		100%
Fee withheld		$ 600,000
Offering expenses paid or payable		$ 700,000
Series B Warrants [Member]
Class Of Stock [Line Items]
Stock issued during period, warrants exercised		0
Series C Warrants [Member]
Class Of Stock [Line Items]
Warrants issued price per share		$ 14
Warrants exercise period		5 years
ATM Offering [Member]
Class Of Stock [Line Items]
Aggregate offering price	$ 7,600,000
Common stock issued (in shares)	333,184
Proceeds from issuance of common stock	$ 2,500,000			$ 400,000
February 2022 Public Offering [Member] | Series A Warrants and Series B Warrants [Member]
Class Of Stock [Line Items]
Warrants issued price per share		$ 14	$ 25
February 2022 Public Offering [Member] | Series A Warrants and Series B Warrants [Member]
Class Of Stock [Line Items]
Estimated fair value of warrants								$ 2,300,000
Offering [Member]
Class Of Stock [Line Items]
Common stock issued (in shares)			190,700
Proceeds from issuance of common stock									$ 9,700,000
Warrants issued price per share				$ 31.25				$ 31.25	$ 31.25
Stock issued during period, warrants exercised					800	1,000
Fee withheld									$ 1,100,000
Offering expenses paid or payable									$ 1,800,000
Number of warrants to issue for purchase of common stock				33,000				33,000	33,000
Percentage of warrants exercise price in the offering									125%
Warrants expire period									5 years
Valuation of warrants									$ 400,000
Expected Volatility									93.25%
Risk-free interest rate									1.81%
Expected dividend yield									0%
Expected term (In Years)									5 years
Offering [Member] | Accrued Expenses [Member]
Class Of Stock [Line Items]
Cash fee for placement agent									$ 900,000
Offering [Member] | Series A Warrants and Series B Warrants [Member]
Class Of Stock [Line Items]
Stock issued during period, warrants exercised						500
Offering [Member] | Series A Warrants [Member]
Class Of Stock [Line Items]
Common stock issued (in shares)			480,052
Warrants issued price per share			$ 25
Stock issued during period, warrants exercised					800
Warrants expire period			1 year
Equity offering description			warrants to purchase one share of common stock
Offering [Member] | Series B Warrants [Member]
Class Of Stock [Line Items]
Common stock issued (in shares)			480,052
Warrants issued price per share			$ 25
Warrants expire period			7 years
Equity offering description			warrants to purchase one share of common stock
Offering [Member] | Series C Warrants [Member]
Class Of Stock [Line Items]
Estimated fair value of warrants			$ 2,300,000
Offering [Member] | Series A Warrants and Series B Warrants [Member]
Class Of Stock [Line Items]
Valuation of warrants			$ 11,600,000
Offering [Member] | Pre-Funded Warrants
Class Of Stock [Line Items]
Common stock issued (in shares)			289,352
Warrants issued price per share			$ 0.005
Stock issued during period, warrants exercised						289,352	289,352
Warrants expire period			20 years
Equity offering description			warrants to purchase one share of common stock
Warrants Repricing [Member]
Class Of Stock [Line Items]
Warrants issued price per share				$ 17.50				$ 17.50	$ 17.50
Percentage of cash compensation for gross proceeds raised									7.50%
Percentage of number of common shares sold to issue warrants									7%
Number of warrants to issue for purchase of common stock				31,000				31,000	31,000
Percentage of warrants exercise price in the offering									125%
Warrants expire period									5 years
Valuation of warrants		$ 400,000							$ 200,000
Expected Volatility		98.90%							96.70%
Risk-free interest rate		2.87%							2.87%
Expected dividend yield		0%							0%
Expected term (In Years)		4 years 7 months 6 days							5 years
Warrants Repricing [Member] | Accrued Expenses [Member]
Class Of Stock [Line Items]
Cash fee for placement agent									$ 500,000
Overallotment Option [Member]
Class Of Stock [Line Items]
Common stock issued (in shares)			24,902
Overallotment option period			45 days
Overallotment Option [Member] | Maximum [Member]
Class Of Stock [Line Items]
Common stock issued (in shares)			72,000
Overallotment Option [Member] | Series A Warrants [Member]
Class Of Stock [Line Items]
Common stock issued (in shares)			72,000
Overallotment Option [Member] | Series A Warrants [Member] | Maximum [Member]
Class Of Stock [Line Items]
Common stock issued (in shares)			72,000
Overallotment Option [Member] | Series B Warrants [Member]
Class Of Stock [Line Items]
Common stock issued (in shares)			72,000
Overallotment Option [Member] | Series B Warrants [Member] | Maximum [Member]
Class Of Stock [Line Items]
Common stock issued (in shares)			72,000

Equity Offerings - Schedule of

Equity Offerings - Schedule of Black-Scholes Option Pricing Model Based on Assumptions (Details)	Jul. 22, 2022	Feb. 08, 2022
Warrants Repricing [Member] | Series A [Member]
Class Of Stock [Line Items]
Risk-free interest rate	2.97%
Volatility	137.87%
Expected dividend yield	0%
Expected life (in years)	7 months 6 days
Warrants Repricing [Member] | Series B [Member]
Class Of Stock [Line Items]
Risk-free interest rate	2.85%
Volatility	90.44%
Expected dividend yield	0%
Expected life (in years)	6 years 7 months 6 days
Warrants Repricing [Member] | Series C Warrants [Member]
Class Of Stock [Line Items]
Risk-free interest rate	2.87%
Volatility	96.70%
Expected dividend yield	0%
Expected life (in years)	5 years
Offering [Member] | Series A [Member]
Class Of Stock [Line Items]
Risk-free interest rate		0.91%
Volatility		131.07%
Expected dividend yield		0%
Expected life (in years)		1 year
Offering [Member] | Series B [Member]
Class Of Stock [Line Items]
Risk-free interest rate		1.93%
Volatility		85.38%
Expected dividend yield		0%
Expected life (in years)		7 years

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Options Activity (Details) - Plans [Member] - Stock Options [Member]	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Options outstanding
Beginning balance | shares	2,168
Canceled/forfeited | shares	(741)
Ending balance | shares	1,427
Exercisable at end of the period | shares	1,251
Vested and expected to vest at end of the period | shares	1,427
Weighted Average Exercise Price
Beginning balance | $ / shares	$ 17,277
Canceled/forfeited | $ / shares	19,266
Ending balance | $ / shares	16,244
Exercisable at the end of period | $ / shares	18,342
Vested and expected to vest at the end of period | $ / shares	$ 16,244
Weighted Average Remaining Life (in years)
Weighted Average Remaining Life (in years)	4 years 25 days
Exercisable at the end of the period	3 years 7 months 6 days
Vested and expected to vest at the end of the period	4 years 25 days

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details) - Plans [Member] - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Restricted Stock Units
Beginning balance | shares	1,400
Vested | shares	(117)
Canceled/forfeited | shares	(1,208)
Ending balance | shares	75
Weighted Average Grant Date Fair Value
Beginning balance | $ / shares	$ 219
Vested | $ / shares	609
Canceled/forfeited | $ / shares	168
Ending balance | $ / shares	$ 416

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Restricted Stock Awards Activity (Details) - Plans [Member] - Restricted Stock Awards (RSAs) [Member]	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance | shares	3,586
Vested | shares	(1,266)
Canceled/forfeited | shares	(966)
Ending balance | shares	1,354
Beginning balance | $ / shares	$ 236
Vested | $ / shares	239
Canceled/forfeited | $ / shares	211
Ending balance | $ / shares	$ 249

Stock-Based Compensation - Sc_4

Stock-Based Compensation - Schedule of Stock-based Compensation Expense Included in Operating Expenses (Details) - Plans [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation in operating expenses	$ 74	$ 105	$ 359	$ 1,802
Selling, General and Administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation in operating expenses	85	78	302	1,551
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation in operating expenses	$ (11)	$ 27	$ 57	$ 251

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation		$ 365,000	$ 1,967,000
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation	$ 5,000	$ 6,000	$ 100,000

Stock-Based Compensation - Sc_5

Stock-Based Compensation - Schedule of Unrecognized Estimated Stock Based Compensation Expense by Award Type (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized Expense	$ 122
Remaining Weighted Average Recognition Period	1 year 3 months 18 days
Restricted Stock Awards (RSAs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized Expense	$ 233
Remaining Weighted Average Recognition Period	1 year 4 months 24 days
Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized Expense	$ 20
Remaining Weighted Average Recognition Period	1 year 2 months 12 days

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)				3 Months Ended	9 Months Ended
	Mar. 18, 2022	Nov. 12, 2021	Dec. 28, 2020	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Loss Contingencies [Line Items]
Revenue				$ 5,000	$ 14,000	$ 17,000
Settlement Agreement
Loss Contingencies [Line Items]
Settlement amount , year 2021			$ 500,000
Settlement year one			2021
Settlement amount , year 2022			$ 750,000
Settlement year two			2022
Settlement amount , year 2023			$ 1,000,000
Settlement year three			2023
Settlement amount , year 2024			$ 1,250,000
Settlement year four			2024
Business acquisition, settlement amount			$ 5,000,000
Business acquisition additional settlement percentage			4%
Business acquisition, transaction costs			$ 100,000,000
Business acquisition change In control payments			28,000,000
Settlement claim			56,000,000
Settlement Agreement | Maximum
Loss Contingencies [Line Items]
Revenue			$ 10,000,000
Securities Class Action and Shareholder Derivative Litigation
Loss Contingencies [Line Items]
Settlement provided for a payment to plaintiff class		$ 10,000,000
Litigation settlement amount	$ 600,000

Restructuring and Impairment _3

Restructuring and Impairment Charges - Schedule of Restructuring and Impairment Charges (Details) - USD ($) $ in Thousands		2 Months Ended	3 Months Ended	9 Months Ended
	Jun. 06, 2022	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2022
Restructuring And Related Activities [Abstract]
Impairment of property and equipment				$ 1,548
Inventory obsolescence				1,000
One-time severance payments	$ 600	$ 300	$ 326	910
Prepaid expenses				395
Contract termination fees			216	216
Total restructuring and impairment charges			$ 542	$ 4,069

Restructuring and Impairment _4

Restructuring and Impairment Charges - Additional Information (Details) - USD ($)		2 Months Ended	3 Months Ended	9 Months Ended
	Jun. 06, 2022	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2022
Restructuring Cost and Reserve [Line Items]
One-time severance payments	$ 600,000	$ 300,000	$ 326,000	$ 910,000
One-time impairment and inventory obsolescence charges and write-off of prepaid research and development supplies				2,900,000
Severance expense		$ 28,000	$ 28,000	$ 28,000
Board of Directors [Member]
Restructuring Cost and Reserve [Line Items]
Percentage of full time employees terminated		20%
Maximum [Member] | Board of Directors [Member]
Restructuring Cost and Reserve [Line Items]
Percentage of full time employees terminated	65%			85%

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($)					1 Months Ended	3 Months Ended
	Oct. 31, 2022	Oct. 24, 2022	Oct. 07, 2022	Sep. 02, 2022	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Aug. 31, 2022
Maximum [Member]
Subsequent Event [Line Items]
Share price per share									$ 0.20
ATM Offering [Member]
Subsequent Event [Line Items]
Sale of common stock				333,184
Net proceeds issuance of common stock				$ 2,500,000	$ 400,000
Common Stock [Member]
Subsequent Event [Line Items]
Sale of common stock						22,000	52,000	1,000
Subsequent Event [Member] | Anaya Holdings LLC [Member] | Lease Termination Agreement [Member]
Subsequent Event [Line Items]
Operating lease, security deposit		$ 36,000
Lease termination fee		$ 300,000
Lease termination effective date		Oct. 28, 2022
Subsequent Event [Member] | Avanti Workspace [Member] | Lease Agreement [Member]
Subsequent Event [Line Items]
Lessee, operating lease, description	On October 31, 2022, the Company entered into a month-to-month lease agreement (the “Lease Agreement”) with Avanti Workspace for its corporate headquarters in Carlsbad, California, effective November 1, 2022. The rent expense under the Lease Agreement is approximately $1,000 per month
Lessee, operating lease, effective date	Nov. 01, 2022
Operating lease rent expense per month	$ 1,000
Subsequent Event [Member] | ATM Offering [Member]
Subsequent Event [Line Items]
Net proceeds issuance of common stock			$ 7,400,000
Stock issuance offering costs			$ 200,000
Subsequent Event [Member] | Common Stock [Member] | ATM Offering [Member]
Subsequent Event [Line Items]
Sale of common stock			1,100,000
Subsequent Event [Member] | Common Stock [Member] | ATM Offering [Member] | Weighted Average [Member]
Subsequent Event [Line Items]
Share price per share			$ 7.09